

UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for ankylosing spondylitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for ankylosing spondylitis.

GREY

Upadacitinib is indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of AS should continue to follow national guidance, local pathways and local formulary choices.

- > NICE Guideline [NG65]: [Spondyloarthritis in over 16s: diagnosis and management](#) (last updated 02 June 2017)
- > NICE Pathway: [Spondyloarthritis](#) (last updated 05 November 2020)
- > Pan Mersey APC Pathway: [Ankylosing Spondylitis \(AS\) and Non-Radiographic Axial Spondyloarthritis \(Axial SpA\) pathway](#) (last updated 23 September 2020)
- > Pan Mersey APC Formulary: [Drugs which suppress the rheumatic disease process](#)

References

1. AbbVie Ltd. Summary of Product Characteristics; [RINVOQ 15 mg prolonged-release tablets](#), 01 January 2021. Accessed online 18 March 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.